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Introduction: The aim of this study was to investigate the incidence 
of radiation pneumonitis in patients with non–small-cell lung cancer 
treated with concurrent thoracic radiotherapy and erlotinib.
Methods: Patients with inoperable stages IIIA to IV non–small-cell 
lung cancer who were treated with concurrent thoracic radiotherapy 
and erlotinib were analyzed. The incidence of radiation pneumoni-
tis was evaluated using the Common Toxicity Criteria (CTC) 3.0 
Grading System. The development of grade 2 or higher radiation 
pneumonitis was the study end point.
Results: Among the 24 patients analyzed, there were nine developed 
radiation pneumonitis of grade 2 or higher (37.5%), including four 
cases of grade 2 radiation pneumonitis (16.7%), two of grade 3 radia-
tion pneumonitis (8.3%), and three of grade 5 radiation pneumonitis 
(12.5%). Three patients developed fatal pneumonia and died of bilat-
eral lung radiation pneumonitis.
Conclusions: Radiation pneumonitis should be considered in 
patients treated with concurrent thoracic radiotherapy and erlotinib.
Key Words: Erlotinib, Thoracic radiotherapy, Radiation pneumoni-
tis, NSCLC.
(J Thorac Oncol. 2014;9: 882–885)
Erlotinib has achieved promising therapeutic efficacy in the treatment of non–small-cell lung cancer.1–3 Thoracic 
radiotherapy is another important therapeutic approach for 
this cancer. Nevertheless, concurrent thoracic radiotherapy 
and erlotinib have been investigated in a limited number of 
studies.4–6 In this study, we summarized the clinical data from 
patients with stages III to IV non–small-cell lung cancer 
treated with concurrent thoracic radiotherapy and erlotinib 
and analyzed the incidence of radiation pneumonitis to pro-
vide guidelines for the treatment of these patients.
MATERIALS AND METHODS
Clinical Data
We collected the medical records of patients with stages 
III to IV non–small-cell lung cancer who received concurrent 
thoracic radiotherapy and erlotinib between September 2009 
and June 2012 (ClinicalTrials.gov Identifier: NCT00973310). 
The inclusion criteria were as follows: (1) patients with stages 
III to IV non–small-cell lung cancer and (2) patients receiving 
concurrent thoracic radiotherapy and erlotinib. The exclusion 
criteria were as follows: (1) patients with non–small-cell lung 
cancer after receiving surgical intervention; (2) patients receiv-
ing re-irradiation therapy; and (3) patients with a history of 
interstitial lung disease. The detailed clinical data of the patients 
are shown in Table 1. This study was conducted in accordance 
with the amended Declaration of Helsinki and was conducted 
under the review, approval, and supervision of Tianjin Cancer 
Hospital. All the enrolled patients met the ethical requirements.
Therapeutic Approach
All patients underwent a computed topography scan for 
positioning, and a precise or pinnacle planning system was 
applied to complete the intensity-modulated radiotherapy. 
The gross tumor volume was contoured during quiet/normal 
breathing at end-inhale and end-exhale phases. The clinical 
target volume (CTV) was defined as subclinical (microscopic) 
disease. Internal target volume was determined from 4-dimen-
sional computed tomography (4DCT) images. The planning 
tumor volume (PTV) was expanded 0.5 cm from the internal 
target volume. The lung organs at risk (OAR) was defined as 
the whole lung volume with the exception of the gross tumor 
volume. The fractionated dose was 1.8 to 2.1 Gy/f (median 
dose, 2 Gy). The dose for thoracic radiotherapy was 46 to 66 
Gy (the dose was prescribed according to the PTV) depend-
ing on the treatment regimen for each patient (some patients 
with stages IIIb–IV non–small-cell lung cancer received pal-
liative therapy). The treatment plan was evaluated using dose–
volume histograms. The dosimetric parameters, including 
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V5, V10, V15, V20, V30, and mean lung dose (MLD), were 
recorded. Patients were treated by fixed-gantry intensity-
modulated radiotherapy. Erlotinib was administered orally at 
150 mg/d from the first day to at least the end of radiotherapy 
(Table 1).
Evaluation of Radiation Pneumonitis
Patients presenting with symptoms of radiation pneu-
monitis were evaluated promptly. The follow-up assessment 
of pulmonary function was conducted on the third week of the 
radiotherapy course and 1 and 3 months after the completion of 
radiotherapy. The follow-up interval was determined by the pres-
ence of radiation pneumonitis and subsequently by the disease 
condition. Nevertheless, follow-up evaluations were performed 
every 3 months (or more often if recommended by the treating 
physician) for the first year after the radiotherapy course and at 
the discretion of the treating physician thereafter. A chest radio-
graph or computed topography scan was performed to evaluate 
the patients’ lung conditions. CTC 3.0 was used as a reference 
to evaluate radiation pneumonitis.7 Radiation pneumonitis 
of grade 2 or above was the primary end point of the study. 
Treatment for radiation pneumonitis was aimed at decreasing 
the inflammation. Steroids, such as methylprednisolone, were 
often administered at 40 to 80 mg once or twice daily until the 
inflammation subsided and then slowly decreased over time.
RESULTS
The Incidence of Radiation Pneumonitis
A total of 24 patients were included in the study with a 
median follow-up duration of 31.5 months (range, 7−48 mo). 
Among these patients, nine (37.5%) had grade 2 or higher 
radiation pneumonitis, including four (16.7%) with grade 2 
radiation pneumonitis, two (8.3%) with grade 3 radiation pneu-
monitis, and three (12.5%) with grade 5 radiation pneumonitis.
Clinical Factors and Lung Dosimetric 
Parameters in the Three Cases 
with Grade 5 Toxicity
Among the patients analyzed, three died from grade 5 
radiation pneumonitis. The basic information on these patients 
including lung dosimetric parameters, erlotinib treatment, and 
occurrence and development of radiation pneumonitis was sum-
marized to provide a reference (Table 2). We emphasized that 
the three pneumonitis fatalities had planning characteristics that 
were acceptable, indicating that the risk of pneumonitis should 
Total taking time of erlotinib (mo)
  Median 3.2
  Range 1.2–27
aThe most frequently used regimen for chemotherapy was cisplatin-based doublet.
DLco, carbon monoxide diffusing capacity; ECOG PS, Eastern Cooperative 
Oncology Group performance status; fVC, forced vital capacity; GTV, gross tumor 
volume; RT, radiotherapy.
TABLE 1. Continued
Factors Value
TABLE 1.  Patient Characteristics and Treatment Modalities
Factors Value
Sex
  Male 9 (38%)
  female 15 (62%)
Age
  Median 64
  Range 33–85
Location
  Upper lobe 14 (58%)
  Middle and lower lobe 10 (42%)
Clinical stage
  IIIA 11 (46%)
  IIIB 7 (29%)
  IV 6 (25%)
ECOG PS
  0 6 (25%)
  1 18 (75%)
fVC
  Median 2.46
  Range 1.4–4.2
fVC1
  Median 1.90
  Range 0.9–3.2
DLco
  Median 2.05
  Range 1.2–4.7
Pathology
  Squamous 5 (21%)
  Adenocarcinoma 17 (71%)
  Adenosquamous carcinoma 1 (4%)
  Sarcomatoid carcinoma 1 (4%)
Radiotherapy dose (Gy)
  Median 57
  Range 46–66
Dose per fraction (Gy)
  Median 2
  Range 1.8–2.1
GTV size (ml)
  Median 35.50
  Range 8.6–454.4
PTV size (ml)
  Median 279.70
  Range 32.9–794.1
Neoadjuvant chemotherapy
  Yesa 13 (54%)
  No 11 (46%)
Adjuvant chemotherapy
  Yesa 12 (50%)
  No 12 (50%)
Taking time of erlotinib concurrent with RT (days)
  Median 41.5
  Range 30–45
(Continued)
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have been low. In addition, it was suggested that erlotinib may 
have contributed to the patients’ risk of radiation pneumonitis.
Imaging Characteristics of the Three Fatalities
As shown in figure 1, severe radiation pneumonitis and 
interstitial lung changes were observed in three patients. The 
images of case 1 showed that both lungs had diffuse infiltra-
tion, which was more obvious in the right lung. The images 
of case 2 showed a poor response of the lesion to treatment, 
despite a decrease in bilateral lung transparency and exten-
sive infiltration. Considering the treatment history, this patient 
showed typical radiation pneumonitis. In the third patient, the 
lesion showed obvious improvement, and widespread patchy 
infiltration of the lung was observed bilaterally. furthermore, 
the infiltration correlated with the radiation fields. In addi-
tion, interstitial lung changes were obvious after the treatment 
(fig. 1). Although all three cases were treated with methyl-
prednisolone, the pneumonitis could not be reversed.
DISCUSSION
The preliminary results of the present study indicate that 
the potential development of radiation pneumonitis should be 
considered in patients treated with concurrent thoracic radio-
therapy and erlotinib.
The combined effect of radiation and erlotinib on the 
pulmonary interstitium was considered to be the cause of radi-
ation pneumonitis. Radiation pneumonitis was caused by radi-
ation damage to type II pneumocytes and the alveolar septum. 
The radiation also caused swelling of the capillary endothe-
lium, interstitial congestion, and alveolar edema, thereby 
resulting in the infiltration of inflammatory cells, desquama-
tion of the alveolar epithelial lining, and protein substance 
exudation caused by interstitial inflammation of the lung.8–10 
Several studies have reported that erlotinib has adverse effects 
on the pulmonary interstitium.11,12 Although the underlying 
mechanism has not yet been fully elucidated and further stud-
ies are required, both erlotinib and radiation can damage the 
pulmonary interstitium. Concurrent therapy might result in 
a synergistic effect of radiation and erlotinib, which further 
increases the risk of radiation pneumonitis.
Some previous study showed that the incidence of radia-
tion pneumonitis is low in patients receiving combination treat-
ment with erlotinib and thoracic radiotherapy.13 Nevertheless, 
this may be related to the smaller lung irradiation volume and 
lower lung radiation dose. Several other studies14,15 reported high 
radiation pneumonitis rates in patients treated with the combi-
nation of erlotinib and radiation, but all the studies had small 
sample sizes, and further reports with a larger number of patients 
are needed. In this study, we not only analyzed the incidence rate 
of radiation pneumonitis but also focused on the fatalities. The 
results provide useful information for physicians and physicists.
In summary, we conducted a valuable investigation of 
radiation pneumonitis in the treatment of concurrent erlotinib 
and thoracic radiotherapy. Our preliminary results indicate 
that patients treated with concurrent thoracic radiotherapy and 
erlotinib should be carefully monitored.
TABLE 2.  Characteristics of the Three Died Cases
Factors Case 1 Case 2 Case 3
Sex Male Male Male
Age (yr) 74 70 65
Pre-RT fVC 2.04 3.78 1.74
Pre-RT fEV1 1.71 3.1 1.41
Pre-RT DLco 3.7 3.27 1.96
Whole lung volume (ml) 3771.4 3369.1 4120
RT dose/fraction 58.8 Gy/28 f 60 Gy/30 f 56 Gy/23 f (unfinished)
GTV size (ml) 26.5 102 111.6
PTV size (ml) 438.9 397.2 794.1
Taking time of erlotinib concurrent with radiotherapy (days) 38 42 32
Total taking time of erlotinib (days) 60 46 32
With vs. without neoadjuvant chemotherapy No No Yes
With vs. without adjuvant chemotherapy No No No
MLD (cGy) 1209 1446 1453
V5 (%) 55 47 67
V10 (%) 40 42 44
V15 (%) 33 23 32
V20 (%) 26 20 26
V30 (%) 14 18 17
Occurrence time of radiation pneumonitis 3 weeks after radiotherapy (21 days) 2 days after the radiotherapy During the radiotherapy
Bilateral or unilateral lung of radiation pneumonitis Bilateral Bilateral Bilateral
Time of onset of symptoms to death 3 weeks (23 days) 1 week (7 days) 6 weeks
RT, radiotherapy; fVC, forced vital capacity; fEV1, forced expiratory volume in 1 second; GTV, gross tumor volume.
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FIGURE 1.  The images and DVHs of the three cases of grade 5 radiation pneumonitis. LL, left lung; RL, right lung; TL, total 
lung; DVHs, dose–volume histograms.
